SCHEMBL997315

SCHEMBL997315

CC(=O)N1CCc2c([nH]c3ncccc23)C1c1cccc(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 2/20 0.47
KIF11 P52732 4/20 0.45
ALDH1A1 P00352 3/20 0.45
TP53 P04637 2/20 0.43
STAT3 P40763 3/20 0.42
SHMT2 P34897 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998488 0.92 ABCB1 (0.56) ABCB1ABCG2MAPTPOLBKIF11
SCHEMBL997683 0.90 MAPT (0.46) ABCB1ABCG2MAPTPOLBALDH1A1
SCHEMBL998836 0.89 KIF11 (0.47) ABCB1ABCG2MAPTPOLBKIF11
SCHEMBL997680 0.87 STAT3 (0.47) ABCB1ABCG2MAPTPOLBKIF11
SCHEMBL1000407 0.85 MEN1 (0.53) ABCB1ABCG2MAPTPOLBKIF11
SCHEMBL998517 0.85 TP53 (0.53) ABCB1ABCG2MAPTPOLBALDH1A1
SCHEMBL997471 0.83 MAPT (0.55) ABCB1ABCG2MAPTPOLBKIF11
SCHEMBL1000663 0.82 ABCB1 (0.56) ABCB1ABCG2MAPTKIF11TP53
SCHEMBL998821 0.82 KIF11 (0.56) ABCB1ABCG2MAPTKIF11TP53
SCHEMBL999692 0.82 ABCB1 (0.54) ABCB1ABCG2MAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed
EP-1637521-A1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS ABCB1 307/4885ABCG2 309/4885MAPT 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.